RBC Capital raised the firm’s price target on Ligand (LGND) to $234 from $185 and keeps an Outperform rating on the shares after “another solid quarter” and 2025 guidance raise.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand price target raised to $220 from $195 at Stifel
- Ligand price target raised to $220 from $175 at Benchmark
- Ligand price target raised to $275 from $250 at Oppenheimer
- Pelthos Therapeutics acquires Xepi Cream from Biofrontera, Ferrer
- Ligand Pharmaceuticals Reports Strong Q3 Results and Raises Guidance